Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Jens Samol(St George's Hospital), Malcolm Ranson(The Christie Hospital), Edwina N. Scott(University of Leicester), Euan Macpherson(AstraZeneca (United Kingdom)), James Carmichael(AstraZeneca (United Kingdom)), Anne Thomas(University of Leicester), James T. Cassidy(Beatson West of Scotland Cancer Centre)
Cited by 158
Abstract
Related Papers
No related papers found
Powered by citation graph analysis